Organigram Global Q1 2026 Organigram Global Inc Earnings Call | AllMind AI Earnings | AllMind AI
Q1 2026 Organigram Global Inc Earnings Call
Speaker #1: for joining us and welcome to the 9. 2026 Earnings ORGANIGRAM Global Q1 Fiscal Call. Hello everyone. we will host a question and answer After today's prepared remarks, Thank you question, please press star 1 on your telephone press star 1 again.
Speaker #1: I will now hand the call over to Max Keypad. To withdraw your question, Schwartz, Director of Investor Relations. Please go ahead.
Operator 1: I will now hand the call over to Max Schwartz, Director of Investor Relations. Please go ahead.
Operator: I will now hand the call over to Max Schwartz, Director of Investor Relations. Please go ahead.
Max Schwartz: Thank you very much, Karen. Good morning, everyone. Thanks for joining us today. As a brief reminder, this call is being recorded, and a replay will be available on our website within 24 hours. Today's call will include forward-looking information, forward-looking statements, and actual results could differ materially due to a number of risk factors outlined in our filings and the cautionary statements included in our Q1 fiscal 2026 press release and MD&A. We'll also reference certain non-IFRS measures such as Adjusted EBITDA, Adjusted Gross Margin, and Free Cash Flow. Definitions and reconciliations are available in our disclosed materials. Unless otherwise noted, market share data is sourced from Hifyre, WeedCrawler, provincial boards, retailers, and our own internal sales tracking. Discussing results today are James Yamanaka, CEO of Organigram, and Greg Guyatt, CFO of Organigram.
Max Schwartz: Thank you very much, Karen. Good morning, everyone. Thanks for joining us today. As a brief reminder, this call is being recorded, and a replay will be available on our website within 24 hours. Today's call will include forward-looking information, forward-looking statements, and actual results could differ materially due to a number of risk factors outlined in our filings and the cautionary statements included in our Q1 fiscal 2026 press release and MD&A. We'll also reference certain non-IFRS measures such as Adjusted EBITDA, Adjusted Gross Margin, and Free Cash Flow. Definitions and reconciliations are available in our disclosed materials. Unless otherwise noted, market share data is sourced from Hifyre, WeedCrawler, provincial boards, retailers, and our own internal sales tracking. Discussing results today are James Yamanaka, CEO of Organigram, and Greg Guyatt, CFO of Organigram.
Speaker #2: much, Karen. Good morning, everyone. As a brief Thanks for joining us hours. Today's call will include forward-looking will be available on our website within 24 results could differ materially due to a number of and the cautionary statements included in
Speaker #2: Press release and MD&A. We'll also reference certain non-IFRS measures such as adjusted EBITDA, adjusted gross margin, and free cash, as well as risk factors outlined in our filings flow.
Speaker #2: Definitions and reconciliations are available in our disclosed materials. Unless otherwise noted, the market share data is sourced information, forward-looking statements, and actual session.
Speaker #2: from high-fire weed-crawler provincial internal sales tracking. boards, retailers, and our own Yamanaka, CEO of ORGANIGRAM, and Greg Dyatt, CFO of our Q1 Fiscal 2026 If you would like to ask a ORGANIGRAM Global.
Max Schwartz: As a reminder, any investor inquiries not addressed on today's call can be directed to investors@organigram.ca. With that, I'll now turn the call over to James. Please go ahead, James.
Max Schwartz: As a reminder, any investor inquiries not addressed on today's call can be directed to investors@organigram.ca. With that, I'll now turn the call over to James. Please go ahead, James.
Speaker #2: investors@organigram.ca.
Speaker #2: James.
James Yamanaka: Thank you, Max, and good morning, everyone. Thanks for joining us today. This is my first earnings call as CEO of Organigram, and I've been encouraged by what I've seen so far. The scale of our operations, the quality of the team, and the depth of capability across the business make it clear why Organigram has grown into Canada's leading cannabis company. Over the past month, I've focused on understanding where Organigram is genuinely strong and where processes can be fine-tuned. I've traveled to our key facilities, met with colleagues across the organization, and I'm learning a great deal while also noting where my 20 years of experience in global strategy within highly regulated markets can be applied. Being part of a leading company in a developing industry is genuinely exciting for me.
James Yamanaka: Thank you, Max, and good morning, everyone. Thanks for joining us today. This is my first earnings call as CEO of Organigram, and I've been encouraged by what I've seen so far. The scale of our operations, the quality of the team, and the depth of capability across the business make it clear why Organigram has grown into Canada's leading cannabis company. Over the past month, I've focused on understanding where Organigram is genuinely strong and where processes can be fine-tuned. I've traveled to our key facilities, met with colleagues across the organization, and I'm learning a great deal while also noting where my 20 years of experience in global strategy within highly regulated markets can be applied. Being part of a leading company in a developing industry is genuinely exciting for me.
Speaker #3: everyone. Thanks for joining us
Speaker #3: Today, this is my first earnings ahead. I've been encouraged by what I've seen so far: the scale of our reminder. Any investor inquiries not addressed, business make it clear why.
Speaker #3: operations, the quality of the team, company in a developing industry is genuinely exciting for me. fragmented and tend to I'll now turn the call over to James.
Speaker #3: ORGANIGRAM has grown into company. Over the past month, I've focused
Speaker #3: Processes can be fine-tuned. I've traveled to our key facilities, and with that, genuinely strong, and where Canada's leading cannabis—and as a thank you. Max, and good morning, highly regulated markets can be—
Speaker #3: Experience in global strategy within long-term growth of the cannabis industry, unlike in more mature industries where the industry—and I'm confident in ORGANIGRAM's ability to compete and lead as that growth continues.
James Yamanaka: Unlike in more mature industries where the market dynamics are less fragmented and tend to move more gradually, cannabis is still very much taking shape. Canada sits at the center of that evolution with global leadership in research, product development, cultivation science, quality, and export activity, areas where Organigram has built meaningful strength while thoughtfully managing the risks associated with maturing markets, regulatory uncertainty, and fragmentation. I'm optimistic about the long-term growth of the cannabis industry, and I'm confident in Organigram's ability to compete and lead as that growth continues. With that, let's turn to some of the developments since last quarter. In Canada, we continue to hold the number one market share position with 11.3% total share in Q1 and 11.7% over the past 12 months.
James Yamanaka: Unlike in more mature industries where the market dynamics are less fragmented and tend to move more gradually, cannabis is still very much taking shape. Canada sits at the center of that evolution with global leadership in research, product development, cultivation science, quality, and export activity, areas where Organigram has built meaningful strength while thoughtfully managing the risks associated with maturing markets, regulatory uncertainty, and fragmentation. I'm optimistic about the long-term growth of the cannabis industry, and I'm confident in Organigram's ability to compete and lead as that growth continues. With that, let's turn to some of the developments since last quarter. In Canada, we continue to hold the number one market share position with 11.3% total share in Q1 and 11.7% over the past 12 months.
Speaker #3: still very much taking shape. Canada sits at the center of that cultivation science, quality, and export activity. applied. Areas where ORGANIGRAM has built on today's call can be directed to met with colleagues across the managing the risks associated with maturing
Speaker #3: With market dynamics are less that, let's turn to some of the uncertainty, while also noting where my 20 years of developments since last quarter.
Speaker #3: In Please go Canada, we continue to hold the number one market share position, with 11.3% total share in Q1 and 11.7% over the past 12 months.
James Yamanaka: Compared to last quarter, we saw a market share decline of approximately 500 basis points, largely due to the impact of the eight-week BC General Employee Union strike, which ended on 26 October. After a brief inventory restock period, our recovery in BC is now complete, and we've regained historical distribution levels. Competition in vapes and IPRs also contributed to the fluctuation in market share, partially offset by growth in flower and concentrate. Nationally, three of our brands, Shred, Boxhot, Holy Mountain, and Big Bag of Buds, maintain their top 10 brand status in Q1, generating over CAD 67 million in retail sales. In Canada's largest markets, we continue to compete strongly, holding the number one position in Ontario, British Columbia, and Alberta. In Quebec, we moved up to the number three position with 9.9% market share for the quarter, exiting December at 10.1%, driven by the success of our vape launches.
James Yamanaka: Compared to last quarter, we saw a market share decline of approximately 500 basis points, largely due to the impact of the eight-week BC General Employee Union strike, which ended on 26 October. After a brief inventory restock period, our recovery in BC is now complete, and we've regained historical distribution levels. Competition in vapes and IPRs also contributed to the fluctuation in market share, partially offset by growth in flower and concentrate. Nationally, three of our brands, Shred, Boxhot, Holy Mountain, and Big Bag of Buds, maintain their top 10 brand status in Q1, generating over CAD 67 million in retail sales. In Canada's largest markets, we continue to compete strongly, holding the number one position in Ontario, British Columbia, and Alberta.
Speaker #3: Levels complete, and we've regained historical distribution. Competition invades in the leadership in research, product development, fluctuation in market share, period, brief inventory restock strike, which ended on October. Concentrate.
Speaker #3: Nationally, three of our buds maintain their top 10 brand status in Q1, generating over talk, hop, and big bag of $67 million evolution, with global flower and sales.
James Yamanaka: In Quebec, we moved up to the number three position with 9.9% market share for the quarter, exiting December at 10.1%, driven by the success of our vape launches.
Speaker #3: launches. We also continue in retail with 9.9% market share for the provinces in Q1. partially offset by growth in to outperform in most other Notably, we held Brunswick, 21.9% in Newfoundland, 12.2% in Nova Scotia.
James Yamanaka: We also continue to outperform in most other provinces in Q1. Notably, we held 33.1% market share in New Brunswick, 21.9% in Newfoundland, 13.4% in Saskatchewan, and 12.2% in Nova Scotia. Category performance varied during the quarter compared to the prior year period. Vapes and IPRs remain the most competitive segments. We maintained the number one position in overall vapes with a 20.4% market share, while in overall pre-rolls, we moved to the number two position at 7.7%, primarily reflecting increased competition in IPRs. In beverages, market share increased 80 basis points year-over-year to 5.9%. In concentrates, Boxhot Whip Diamond and Organigram Innovation became the number one dabbable concentrate in Canada, contributing to a 15.5% category share. In edibles, we gained 2.4 points year-over-year to reach 17.9% share, with Shred becoming the number two gummy brand in the country in December.
James Yamanaka: We also continue to outperform in most other provinces in Q1. Notably, we held 33.1% market share in New Brunswick, 21.9% in Newfoundland, 13.4% in Saskatchewan, and 12.2% in Nova Scotia. Category performance varied during the quarter compared to the prior year period. Vapes and IPRs remain the most competitive segments. We maintained the number one position in overall vapes with a 20.4% market share, while in overall pre-rolls, we moved to the number two position at 7.7%, primarily reflecting increased competition in IPRs. In beverages, market share increased 80 basis points year-over-year to 5.9%. In concentrates, Boxhot Whip Diamond and Organigram Innovation became the number one dabbable concentrate in Canada, contributing to a 15.5% category share. In edibles, we gained 2.4 points year-over-year to reach 17.9% share, with Shred becoming the number two gummy brand in the country in December.
Speaker #3: Compared to the prior year period, vapes and IPRs remain the most competitive. Performance varied during the quarter compared to the segments. We maintain the number one position in overall vapes with a 33.1% market share, while in overall pre-rolls we moved to the number two position in IPRs.
Speaker #3: In IPRs also contributed to the 20.4% market competition in beverages, market share increased 80 basis points year over year to 5.9%. In concentrates, box hop whipped diamond, and ORGANIGRAM Innovation, concentrate in Canada contributing to became the number one dabbable a 15.5% 13.4% in Saskatchewan, and primarily reflecting increased edibles, we gained 2.4 points year over year to reach 17.9% share, with shred becoming the number two gummy brand in the country in December.
Speaker #3: Finally, in whole flower, market share increased 90 basis points year over year to 7.3%, driven by continued strength in our big bag brands. innovation pipeline is beginning to Our new category share.
James Yamanaka: Finally, in whole flower, market share increased 90 basis points year-over-year to 7.3%, driven by continued strength in our Big Bag brands. Our new innovation pipeline is beginning to reach distribution in the second quarter. This includes new competitive coated IPRs and the launches of Shred's Soda and Shred's Shots, powered by a fast-acting soluble technology developed in the product development center. A key differentiator for Shred's Shots relative to comparable products is our on-package claim of a 15-minute onset. We believe this meaningfully lowers the barrier to trial for consumers, supports retailer decisions around shelf space, and, with a smaller liquid format paired with a fast, predictable dose, positions Shots as a discrete and convenient option that competes effectively with other ingestible categories, including gummies. Turning to operations, we continue to make progress in plant science and scale.
James Yamanaka: Finally, in whole flower, market share increased 90 basis points year-over-year to 7.3%, driven by continued strength in our Big Bag brands. Our new innovation pipeline is beginning to reach distribution in the second quarter. This includes new competitive coated IPRs and the launches of Shred's Soda and Shred's Shots, powered by a fast-acting soluble technology developed in the product development center. A key differentiator for Shred's Shots relative to comparable products is our on-package claim of a 15-minute onset. We believe this meaningfully lowers the barrier to trial for consumers, supports retailer decisions around shelf space, and, with a smaller liquid format paired with a fast, predictable dose, positions Shots as a discrete and convenient option that competes effectively with other ingestible categories, including gummies. Turning to operations, we continue to make progress in plant science and scale.
Speaker #3: quarter. This includes new competitive coated IPRs and the launches of shred soda, and shred shots, powered by our fast-acting soluble In reach distribution in the second product development shots relative to comparable center.
Speaker #3: products is our on-package claim of a 15-minute onset. We believe this meaningfully lowers the barrier to trial for consumers, technology developed in the liquid format paired with a fast space, and with a smaller predictable dose, position shots as a discrete and convenient A key differentiator for shred option that competes effectively with other ingestible categories including gummies.
Speaker #3: Turning to operations, operations we continue to make progress in plant science and scale. In Q1, we harvested over 28,000 kilograms of flour, representing a 43% year over year increase.
James Yamanaka: In Q1, we harvested over 28,000kg of flower, representing a 43% year-over-year increase. This growth was a result of improving yields, driven by our LED lighting conversion project, which was partially funded by Opportunities New Brunswick, as well as ongoing refinements to our nutrient programs. Alongside these gains, continued progress in our breeding efforts drove average flower THC levels to a quarterly high of over 29%. Achieving that level of potency at our operating scale is meaningful. In addition, 38% of lots tested in Q1 exceeded 30% THC. Today, we are also announcing a proprietary breakthrough in Powdery Mildew resistance. Our plant science teams have identified a genetic marker that can be screened in early seedling populations, allowing us to avoid investing time and capital in plants that will never express this resistance trait. Previously, confirming mildew resistance required approximately 90 days.
James Yamanaka: In Q1, we harvested over 28,000kg of flower, representing a 43% year-over-year increase. This growth was a result of improving yields, driven by our LED lighting conversion project, which was partially funded by Opportunities New Brunswick, as well as ongoing refinements to our nutrient programs. Alongside these gains, continued progress in our breeding efforts drove average flower THC levels to a quarterly high of over 29%. Achieving that level of potency at our operating scale is meaningful. In addition, 38% of lots tested in Q1 exceeded 30% THC. Today, we are also announcing a proprietary breakthrough in Powdery Mildew resistance. Our plant science teams have identified a genetic marker that can be screened in early seedling populations, allowing us to avoid investing time and capital in plants that will never express this resistance trait. Previously, confirming mildew resistance required approximately 90 days.
Speaker #3: This growth was a result of improving yields, driven by our LED lighting conversion project, which was partially funded by opportunities in New Brunswick, as well as ongoing refinements to our nutrient programs.
Speaker #3: Alongside these gains, continued progress in our breeding efforts drove average flower THC levels to a quarterly high of over 29%. Achieving that level of potency at our operating scale is meaningful.
Speaker #3: In addition, 38% of lots tested in Q1 exceeded 30% THC. Today, we are also in powdery mildew announcing a proprietary breakthrough have identified a genetic marker that can be screened in early seedling population, allowing us to resistance.
Speaker #3: avoid investing time and capital in plants that will never express this resistance trait. days; with this discovery, screening resistance required approximately 90 days enabling a total enabling Previously, confirming mildew can now occur within 10 populations and reducing downstream crop loss and waste.
James Yamanaka: With this discovery, screening can now occur within 10 days, enabling early removal of out-of-spec populations and reducing downstream crop loss and waste. This screening tool is proprietary and applicable across a wide range of genetics, unlike existing markers that are limited in scope. When combined with our seed-based breeding initiatives, which represent approximately 30% of harvest in the quarter, these advances support more stable genetics, higher realized yields, and improved cost efficiency, contributing to our expected margin expansion over time. On the manufacturing side, we continue to optimize our hydrocarbon extraction and pre-roll production. 100% of our extraction is now hydrocarbon-based, with capacity up 87% year-over-year and lower associated COGS. Focusing on hydrocarbon extraction allows us to meet increasing derivative needs internally while expanding B2B opportunities.
James Yamanaka: With this discovery, screening can now occur within 10 days, enabling early removal of out-of-spec populations and reducing downstream crop loss and waste. This screening tool is proprietary and applicable across a wide range of genetics, unlike existing markers that are limited in scope. When combined with our seed-based breeding initiatives, which represent approximately 30% of harvest in the quarter, these advances support more stable genetics, higher realized yields, and improved cost efficiency, contributing to our expected margin expansion over time. On the manufacturing side, we continue to optimize our hydrocarbon extraction and pre-roll production. 100% of our extraction is now hydrocarbon-based, with capacity up 87% year-over-year and lower associated COGS. Focusing on hydrocarbon extraction allows us to meet increasing derivative needs internally while expanding B2B opportunities.
Speaker #3: This screening tool is proprietary and applicable across a wide range of genetics. Our plant science team's limited in scope. When combined, unlike existing markers that are with our seed-based breeding, approximately 30% of harvest in the quarter, these advances support more stable genetics and higher realized yields and improve cost efficiency, contributing to expansion over time.
Speaker #3: This screening tool is proprietary and applicable across a wide range of genetics, Our plant science teams limited in scope. When combined unlike existing markers that are with our seed-based breeding approximately 30% of harvest in the quarter, these advances support more stable genetics and higher realized yields and improve cost efficiency contributing expansion over time. initiatives, which represent On the manufacturing side, we continue to optimize our hydrocarbon extraction and pre-roll production.
Speaker #3: 100% of our extraction is now hydrocarbon-based, with capacity up 87% year on year, and, to our expectation, margin-lower associated COGS. Focusing on hydrocarbon internally while expanding B2B opportunities.
Speaker #3: extraction allows us to meet improvements should begin to flow more move further into fiscal meaningfully through our P&L As we as lower-cost inventory moves through a more efficient distribution due to the ongoing optimization of our recent ERP upgrades.
Speaker #3: In increasing derivative needs in Winnipeg, we have completed commissioning of our beverage line and are beginning in-house production for a portion of our beverage portfolio to support its expansion.
James Yamanaka: In Winnipeg, we have completed commissioning of our beverage line and are beginning in-house production for a portion of our beverage portfolio to support its expansion. As we move further into fiscal 2026, the benefits of these improvements should begin to flow more meaningfully through our P&L as lower-cost inventory moves through a more efficient distribution due to the ongoing optimization of our recent ERP upgrades. Moving to our international business, in Q1, we generated CAD 5 million in international sales, up 55% from Q1 fiscal 2025. We did see an unanticipated sequential decline in the international volumes during the quarter. This was primarily driven by a higher-than-expected proportion of flower that did not meet international specifications. While some level of out-of-spec product is expected, we've taken steps to remediate this temporary issue, return to normal operating parameters, and reduce the risk of future variability.
James Yamanaka: In Winnipeg, we have completed commissioning of our beverage line and are beginning in-house production for a portion of our beverage portfolio to support its expansion. As we move further into fiscal 2026, the benefits of these improvements should begin to flow more meaningfully through our P&L as lower-cost inventory moves through a more efficient distribution due to the ongoing optimization of our recent ERP upgrades. Moving to our international business, in Q1, we generated CAD 5 million in international sales, up 55% from Q1 fiscal 2025. We did see an unanticipated sequential decline in the international volumes during the quarter. This was primarily driven by a higher-than-expected proportion of flower that did not meet international specifications. While some level of out-of-spec product is expected, we've taken steps to remediate this temporary issue, return to normal operating parameters, and reduce the risk of future variability.
Speaker #3: Moving to Q1, we generated $5 million in international sales. $5 million in international sales is up 55% to our international business in 2025. We did see an unanticipated sequential decline in the international volumes during the quarter; this was primarily driven by meeting international specifications.
Speaker #3: from Q1 fiscal issue. Return to normal operating While some level of taken steps to remediate this temporary parameters and reduce the risk of future higher-than-expected proportion of flour that did not variability.
James Yamanaka: We remain optimistic about international momentum and continue to expect meaningful international sales growth in fiscal 2026 as demand remains elevated. Regarding our expected EU GMP certification, we are preparing follow-up responses and information from the regulator in response to feedback received in January 2026. Following provision of this information, the company expects to await confirmation of certification or any required next steps. On international branded sales, we continue to make progress. In Australia, we shipped input materials for vape production and distribution in December, completing the first production run in January, and now are in the process of launching. In the US, we launched Collective Project and Fetch in Illinois and Wisconsin through new distribution partners, expanding our retail footprint to 11 states. We are also continuing to pursue marketing and distribution expansion for our Happi gummies.
James Yamanaka: We remain optimistic about international momentum and continue to expect meaningful international sales growth in fiscal 2026 as demand remains elevated. Regarding our expected EU GMP certification, we are preparing follow-up responses and information from the regulator in response to feedback received in January 2026. Following provision of this information, the company expects to await confirmation of certification or any required next steps. On international branded sales, we continue to make progress. In Australia, we shipped input materials for vape production and distribution in December, completing the first production run in January, and now are in the process of launching. In the US, we launched Collective Project and Fetch in Illinois and Wisconsin through new distribution partners, expanding our retail footprint to 11 states. We are also continuing to pursue marketing and distribution expansion for our Happi gummies.
Speaker #3: about international momentum and continue to expect meaningful We remain optimistic 2026 as demand remains elevated. Regarding our expected EU GMP certification, we international sales growth in fiscal are preparing follow-up responses and information from the regulator in response to feedback received in January company expects to await confirmation 2026.
Speaker #3: of certification or any required next steps. On international branded sales, we continue to make in December, completing the first progress. production run in January, and In Australia, we shipped input now are in the process of launching.
Speaker #3: In the US, we launched collective project and fetch in materials for vape production and distribution Following provision of this information, the our retail footprint to 11 to pursue marketing and distribution expansion for our happily Illinois and Wisconsin, through states. gummies.
Speaker #3: In the US, we launched collective project and fetch in materials for vape production and distribution Following provision of this information, the our retail footprint to 11 to pursue marketing and distribution expansion for our happily Illinois and Wisconsin, through states.
James Yamanaka: In both cases, our penetration to the US has been slower than anticipated, reflecting a rapidly evolving market with increasing competition and ongoing regulatory developments. With Collective Project, Fetch, and Happi products collectively available in over 20 states through DTC and retail channels, we do anticipate the incremental growth in line with the market, but we are not relying on the US market for growth. We continue to closely monitor regulatory changes in the US and are closely following recent efforts from lawmakers to amend or extend existing limitations on intoxicating hemp products. So overall, we are pleased with our year-over-year growth. And despite sequentially lower international sales, typical seasonality, and the impact of the BC labor strike, we maintain adjusted gross margins in line with our record-breaking Q4 and fiscal 2025. As the year progresses, we remain confident in our ability to deliver against our previously issued guidance.
James Yamanaka: In both cases, our penetration to the US has been slower than anticipated, reflecting a rapidly evolving market with increasing competition and ongoing regulatory developments. With Collective Project, Fetch, and Happi products collectively available in over 20 states through DTC and retail channels, we do anticipate the incremental growth in line with the market, but we are not relying on the US market for growth. We continue to closely monitor regulatory changes in the US and are closely following recent efforts from lawmakers to amend or extend existing limitations on intoxicating hemp products. So overall, we are pleased with our year-over-year growth. And despite sequentially lower international sales, typical seasonality, and the impact of the BC labor strike, we maintain adjusted gross margins in line with our record-breaking Q4 and fiscal 2025. As the year progresses, we remain confident in our ability to deliver against our previously issued guidance.
Speaker #3: The rapidly evolving market, with increasing anticipation, reflects that penetration of the US has been slower than regulatory developments. With collective product, Fetch, and Happily, we are also continuing with product collectively available in over 20 states through D2C and retail channels. We do anticipate incremental growth in line with the market.
Speaker #3: But we are not reliant on the US market for growth. We continue to closely monitor US and are closely following recent efforts from lawmakers to amend or extend existing limitations on intoxicating hemp regulatory changes in the our year-over-year growth, and despite impact of the BC labor products. fiscal 2025.
Speaker #3: But we are not reliant on the US market for growth. We continue to closely monitor US and are closely following recent efforts from lawmakers to amend or extend existing limitations on intoxicating hemp regulatory changes in the our year-over-year growth, and despite impact of the BC labor products.
Speaker #3: Confident in our ability to deliver against our previously issued guidance. With that, I'll turn over the call to Greg to walk through our financial performance. Overall, we are pleased with—Greg?
James Yamanaka: With that, I'll turn over the call to Greg to walk through our financial performance. Greg.
James Yamanaka: With that, I'll turn over the call to Greg to walk through our financial performance. Greg.
Speaker #5: Thank you, James. Great to have you on board for our first earnings call
Greg Guyatt: Thank you, James. Great to have you on board for our first earnings call together. Good morning, everyone. Before getting into the numbers, I'll briefly frame Q1. Results reflected strong year-over-year revenue and Adjusted EBITDA growth alongside the usual seasonal reset from Q4, as we discussed last earnings call, with some incremental pressure from the operational and market factors James mentioned. Importantly, none of these dynamics change our expectations for the rest of the year. Our business has historically delivered stronger fundamental performance in the second half of the fiscal year, particularly in Q3 and Q4. Based on our recent visibility and execution based on our current visibility and execution plans, we remain on track to deliver against our full-year guidance. With that, let's turn to the quarter.
Greg Guyatt: Thank you, James. Great to have you on board for our first earnings call together. Good morning, everyone. Before getting into the numbers, I'll briefly frame Q1. Results reflected strong year-over-year revenue and Adjusted EBITDA growth alongside the usual seasonal reset from Q4, as we discussed last earnings call, with some incremental pressure from the operational and market factors James mentioned. Importantly, none of these dynamics change our expectations for the rest of the year. Our business has historically delivered stronger fundamental performance in the second half of the fiscal year, particularly in Q3 and Q4. Based on our recent visibility and execution based on our current visibility and execution plans, we remain on track to deliver against our full-year guidance. With that, let's turn to the quarter.
Speaker #5: together. Good morning, everyone. So Before getting into the numbers, I'll
Speaker #5: Q1 results reflected strong year-over-year revenue and adjusted EBITDA growth, alongside the usual seasonal reset from Q4, as we discussed last earnings call, with some incremental pressure from the operational and market factors James mentioned.
Speaker #5: Importantly, none of typical seasonality and the expectations for the rest of the delivered stronger fundamental performance in the second half of the fiscal year.
Speaker #5: year, particularly in Q3 and Q4. Based on our recent visibility and execution plans, we remain on track to deliver against our full-year guidance. Our business has historically performed well based on our current visibility and execution plans.
Speaker #5: With that, let's turn to the quarter. In Q1, net revenue increased 49% to $65.3 million, from $42.7 million in the same prior-year period, primarily due to growth in our Canadian business, the integration of Motif, and higher International sales for Q1 were $5 international sales.
Greg Guyatt: In Q1, net revenue increased 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in our Canadian business, the integration of Motif, and higher international sales. International sales for Q1 were CAD 5 million, up 51% over Q1 last year. Sequentially, net revenue decreased 21%. The decrease was primarily due to our seasonally lower Q1. As James mentioned, Q1 was also negatively impacted by the BC employee strike, increased competition in vapes and pre-rolls, and sequentially lower international sales. Adjusted gross profit for the quarter increased 67% to CAD 23.9 million versus CAD 14.3 million in Q1 last year due to our significantly higher revenue base, international sales growth, and incremental efficiency gains.
Greg Guyatt: In Q1, net revenue increased 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in our Canadian business, the integration of Motif, and higher international sales. International sales for Q1 were CAD 5 million, up 51% over Q1 last year. Sequentially, net revenue decreased 21%. The decrease was primarily due to our seasonally lower Q1. As James mentioned, Q1 was also negatively impacted by the BC employee strike, increased competition in vapes and pre-rolls, and sequentially lower international sales. Adjusted gross profit for the quarter increased 67% to CAD 23.9 million versus CAD 14.3 million in Q1 last year due to our significantly higher revenue base, international sales growth, and incremental efficiency gains.
Speaker #5: Q1 last year. Sequentially, net revenue decreased 21%. The decrease was primarily due to seasonal to our seasonally lower Q1. As James mentioned, Q1 was also negatively impacted by the BC competition in vapes and pre-rolls, employee strike, increased and sequentially lower international sales.
Speaker #5: Adjusted gross profit for the quarter increased 67% to $23.9 million versus $14.3 million in Q1 last year, due to our significantly higher gains. We are pleased to report impacts on revenue, as well as growth and incremental efficiency lower levels of high-margin international sales, adjusted gross margin remains stable sequentially at 38%, an increase of 500 basis points over Q1 yields, lower cultivation last year.
Speaker #5: Revenue-based international sales synergy realization as we started to sell costs, and Motif through lower-cost inventory. This demonstrates that our investments in efficiency are having a positive impact on cost per gram and margins, which we anticipate to continue to expand as international volumes scale throughout the year.
Greg Guyatt: We are pleased to report that despite seasonal and competitive impacts on revenue, as well as lower levels of high-margin international sales, adjusted gross margin remained stable sequentially at 38%, an increase of 500 basis points over Q1 last year. Adjusted gross margin was supported by higher yields, lower cultivation costs, and Motif synergy realization as we started to sell through lower-cost inventory. This demonstrates that our investments in efficiency are having a positive impact on cost per gram and margins, which we anticipate continuing to expand as international volumes scale throughout the year. In Q1, G&A costs were CAD 15 million versus CAD 11.2 million in the prior year period. The 33% year-over-year increase in G&A is primarily associated with the consolidation of Motif's costs for the full quarter, incremental ERP and professional fees, higher depreciation and amortization, but partially offset by cost savings initiatives.
Greg Guyatt: We are pleased to report that despite seasonal and competitive impacts on revenue, as well as lower levels of high-margin international sales, adjusted gross margin remained stable sequentially at 38%, an increase of 500 basis points over Q1 last year. Adjusted gross margin was supported by higher yields, lower cultivation costs, and Motif synergy realization as we started to sell through lower-cost inventory. This demonstrates that our investments in efficiency are having a positive impact on cost per gram and margins, which we anticipate continuing to expand as international volumes scale throughout the year. In Q1, G&A costs were CAD 15 million versus CAD 11.2 million in the prior year period. The 33% year-over-year increase in G&A is primarily associated with the consolidation of Motif's costs for the full quarter, incremental ERP and professional fees, higher depreciation and amortization, but partially offset by cost savings initiatives.
Speaker #5: Q1 G&A costs were $15 million versus $11.2 million in the prior-year period. The 33% year-over-year increase in G&A is primarily associated with the consolidation of Motif's costs for ERP and professional fees, higher depreciation, and the full quarter incremental amortization, but partially offset by cost savings initiatives.
Speaker #5: As we're in the final phases of ERP that project to roll off after the second quarter. As G&A costs represented roughly implementation, we expect the associated costs with 200 basis points from the same prior-year costs were $9 million, versus period.
Greg Guyatt: As we're in the final phases of ERP implementation, we expect the associated costs with that project to roll off after the second quarter. As a proportion of net revenue, G&A costs represented roughly 24% of net revenue in Q1, which was down approximately 200 basis points from the same prior year period. Sales and marketing costs were CAD 9 million versus CAD 5.8 million in the same prior year period. Similar to G&A, the year-over-year increase is primarily attributable to supporting the addition of Motif and Collective Project brand portfolios. Sales and marketing costs represented 14% of net revenue, up approximately 500 basis points year over year. Overall, SG&A declined by 200 basis points year over year as a percentage of net revenue, reflecting continued scale and operating leverage, partially offset by higher trade investment to support competitive activity.
Greg Guyatt: As we're in the final phases of ERP implementation, we expect the associated costs with that project to roll off after the second quarter. As a proportion of net revenue, G&A costs represented roughly 24% of net revenue in Q1, which was down approximately 200 basis points from the same prior year period. Sales and marketing costs were CAD 9 million versus CAD 5.8 million in the same prior year period. Similar to G&A, the year-over-year increase is primarily attributable to supporting the addition of Motif and Collective Project brand portfolios. Sales and marketing costs represented 14% of net revenue, up approximately 500 basis points year over year. Overall, SG&A declined by 200 basis points year over year as a percentage of net revenue, reflecting continued scale and operating leverage, partially offset by higher trade investment to support competitive activity.
Speaker #5: period. Similar to G&A, the $5.8 million in the same prior-year attributable to supporting the addition of Motif and collective brand product year-over-year increase is primarily or collective project brand Sales and marketing portfolios.
Speaker #5: Sales and marketing costs represented 14% of net revenue, up approximately 500 basis points year-over-year. Overall, SG&A declined by 200 basis points year-over-year as a percentage of net operating leverage, partially offset revenue, reflecting continued scale and by higher trade investment to support expectation remains that SG&A costs will continue to decline competitive activity.
Greg Guyatt: Our expectation remains that SG&A costs will continue declining incrementally relative to net revenue as the year progresses, all else being equal. Total operating expenses for the quarter were CAD 26.7 million or 42% of net revenue, a year-over-year decrease of 600 basis points, primarily due to lower proportional G&A costs and lower R&D spending. Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale, higher international sales, and proportionally lower operating expenses. Sequentially, adjusted EBITDA declined primarily due to our lower international sales, the now-resolved revenue disruption in British Columbia, and, as previously mentioned, our normal seasonal dynamics. Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period.
Greg Guyatt: Our expectation remains that SG&A costs will continue declining incrementally relative to net revenue as the year progresses, all else being equal. Total operating expenses for the quarter were CAD 26.7 million or 42% of net revenue, a year-over-year decrease of 600 basis points, primarily due to lower proportional G&A costs and lower R&D spending. Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale, higher international sales, and proportionally lower operating expenses. Sequentially, adjusted EBITDA declined primarily due to our lower international sales, the now-resolved revenue disruption in British Columbia, and, as previously mentioned, our normal seasonal dynamics. Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period.
Speaker #5: revenue, as the year progresses, all else being equal. Total incrementally relative to net operating expenses for the quarter were $26.7 million or $42% Our decrease of 600 basis points, primarily due to lower proportional G&A costs and lower R&D spending.
Speaker #5: $5.3 million, up in the prior-year period, driven by increased scale, 273% from $1.4 million higher international sales, and proportionally lower operating expenses. Sequentially, adjusted of net revenue, a year-over-year EBITDA declined primarily due to our lower international sales, the Columbia, and, as previously now resolved revenue disruption in British mentioned, our normal seasonal Adjusted EBITDA in Q1 was the quarter was $20 million, compared to a net loss of $23 The $43 million year-over-year improvement million in the same prior-year period.
Greg Guyatt: The CAD 43 million year-over-year improvement was primarily due to changes in the fair value of derivative liabilities and top-up rights associated with our follow-on BAT investment. From a cash flow perspective, in Q1, cash provided by operating activities before working capital changes was CAD 0.3 million compared to cash used at CAD 6.3 million in the prior year period, demonstrating improved cash generation from the core business supporting our full-year guidance of positive free cash flow. Cash used by operations after working capital changes was CAD 16 million versus cash used of CAD 4.2 million in Q1 last year. The increase in cash used was driven by investments in working capital related to higher inventory levels as we completed the migration of our new ERP enhancements and the timing of excise duties and Health Canada licensing payments that occurred in the first quarter.
Greg Guyatt: The CAD 43 million year-over-year improvement was primarily due to changes in the fair value of derivative liabilities and top-up rights associated with our follow-on BAT investment. From a cash flow perspective, in Q1, cash provided by operating activities before working capital changes was CAD 0.3 million compared to cash used at CAD 6.3 million in the prior year period, demonstrating improved cash generation from the core business supporting our full-year guidance of positive free cash flow. Cash used by operations after working capital changes was CAD 16 million versus cash used of CAD 4.2 million in Q1 last year. The increase in cash used was driven by investments in working capital related to higher inventory levels as we completed the migration of our new ERP enhancements and the timing of excise duties and Health Canada licensing payments that occurred in the first quarter.
Speaker #5: fair value of derivative liabilities and From a cash flow perspective, in top-up rights associated with our activities before working capital changes was $0.3 million, compared to cash used at $6.3 demonstrating improved cash generation from the million in the prior-year period, core business supporting our full-year guidance of positive free cash by operations after working capital changes was $16 million, flow.
Speaker #5: Cash used Finally, as of quarter end, we held inventory levels, as we completed the total cash and short-term investments of excise duties and Health Canada quarter.
Speaker #5: increase in cash used was driven by investments in working capital, related to higher in Q1 last year. The migration of our new ERP follow-on VAT investment.
Greg Guyatt: Finally, as of quarter end, we held total cash and short-term investments of CAD 63 million, including CAD 7.6 million of unrestricted cash. We are confident in our ability to generate cash from operations and Free Cash Flow in the near term and are assessing non-dilutive sources of capital to support liquidity and financial flexibility. To wrap up, in Q1, we delivered strong year-over-year growth in revenue and Adjusted EBITDA, maintained stable sequential margins at 38%, and continued to demonstrate operating leverage as the organization continues to scale. Our margin performance this quarter underscores the progress we're making on efficiency, cost structure, and Motif integration, and we expect these benefits to become increasingly visible as higher-margin international volumes scale through the back half of the year.
Greg Guyatt: Finally, as of quarter end, we held total cash and short-term investments of CAD 63 million, including CAD 7.6 million of unrestricted cash. We are confident in our ability to generate cash from operations and Free Cash Flow in the near term and are assessing non-dilutive sources of capital to support liquidity and financial flexibility. To wrap up, in Q1, we delivered strong year-over-year growth in revenue and Adjusted EBITDA, maintained stable sequential margins at 38%, and continued to demonstrate operating leverage as the organization continues to scale. Our margin performance this quarter underscores the progress we're making on efficiency, cost structure, and Motif integration, and we expect these benefits to become increasingly visible as higher-margin international volumes scale through the back half of the year.
Speaker #5: $7.6 million of unrestricted cash. We are confident in our ability to enhancements and the timing of our assessing non-dilutive sources of licensing payments that occurred in the first capital to support liquidity and financial flexibility.
Speaker #5: To wrap up, in Q1 we delivered strong year-over-year growth in free cash flow in the near term, at $63 million, including revenue and adjusted EBITDA, maintained stable sequentially, and continued to demonstrate operating scale.
Speaker #5: Our margin performance this quarter underscores the progress we're making on efficiency, cost integration, and we expect these benefits to become structural and more visible as higher-margin international volumes scale through the back half of the year, providing further leverage as the organization continues to grow.
Speaker #5: While working capital weighed on cash usage in the quarter, cash generation from the core business continues to improve, and we remain confident in our ability to deliver positive free cash flow for the full year.
Greg Guyatt: While working capital weighed on cash usage in the quarter, cash generation from the core business continues to improve, and we remain confident in our ability to deliver positive free cash flow for the full year. We remain on track to deliver against our full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals, expanding margins, and a disciplined approach to capital and liquidity. With that, we'd be happy to open the call for questions. Sorry, I'll get to questions in a moment. Our moderator is just having an issue on their end. Just give us one moment to resolve. Thanks. All right. While that issue resolves, I will kick off questions here. I believe our first question is from Brenda Cunningham at ATB.
Greg Guyatt: While working capital weighed on cash usage in the quarter, cash generation from the core business continues to improve, and we remain confident in our ability to deliver positive free cash flow for the full year. We remain on track to deliver against our full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals, expanding margins, and a disciplined approach to capital and liquidity. With that, we'd be happy to open the call for questions. Sorry, I'll get to questions in a moment. Our moderator is just having an issue on their end. Just give us one moment to resolve. Thanks. All right. While that issue resolves, I will kick off questions here. I believe our first question is from Brenda Cunningham at ATB.
Speaker #5: We remain on track to deliver against our full-year guidance of revenue exceeding $300 million, supported by improving fundamentals, expanding margins, and a disciplined approach to capital and liquidity. With that, we'd be happy to open the call for questions.
Speaker #5: questions.
Speaker #6: Sorry, I will get to questions in a moment. on their end. Just give us one moment to resolve. Our moderator is just having an issue
Speaker #6: Thanks. All right. While that issue resolves, I will kick off questions here, and I believe our first question is from Brenda Cunningham at ATB.
Speaker #7: We are experiencing technical difficulties and have placed the call on hold.
Operator 2: We are experiencing technical difficulties and have placed the call on hold.
Operator: We are experiencing technical difficulties and have placed the call on hold.
Speaker #8: Hi there, everybody. This is Devin from Q4. I'm going to sub in for Kara right now. She's just having some technical difficulties. Can so Aaron Gray currently on stage.
Operator 3: Hi there, everybody. This is Devin from Q4. I'm going to sub in for Kara right now. She's just having some technical difficulties. So going ahead with the Q&A, we have Aaron Grey currently on stage. Your line is open. Please go ahead. Aaron, if you're muted locally, just please unmute yourself. You're still on stage.
Operator: Hi there, everybody. This is Devin from Q4. I'm going to sub in for Kara right now. She's just having some technical difficulties. So going ahead with the Q&A, we have Aaron Grey currently on stage. Your line is open. Please go ahead. Aaron, if you're muted locally, just please unmute yourself. You're still on stage.
Speaker #8: Open. Please go ahead with the Q&A. Your line is open. Aaron, if you're muted locally, just please unmute yourself. You're still on stage.
Aaron Grey: Hi. Can you guys hear me okay?
Aaron Grey: Hi. Can you guys hear me okay?
Speaker #9: Can you guys hear me okay? So I guess first question for me is, now that you've kind of started to you back in the industry now.
Speaker #8: There
Operator 3: There we go. Yep, we can hear you.
Operator: There we go. Yep, we can hear you.
Speaker #9: Okay.
Aaron Grey: Okay. Perfect. All right. Fantastic. Thanks so much for the questions here. James, welcome aboard. Great to have you back in the industry now. So I guess first question for me is, now that you've kind of started to get your feet, I know still early days, but it sounds like you've been touring a lot of facilities and getting a better feel for the business. It would be great to kind of hear in terms of where are you seeing some of the lower-hanging near-term opportunities versus some of the initiatives that might be more long-term in nature, and how we should think about maybe how you're level-setting prioritization of those initiatives. Thanks.
Aaron Grey: Okay. Perfect. All right. Fantastic. Thanks so much for the questions here. James, welcome aboard. Great to have you back in the industry now. So I guess first question for me is, now that you've kind of started to get your feet, I know still early days, but it sounds like you've been touring a lot of facilities and getting a better feel for the business. It would be great to kind of hear in terms of where are you seeing some of the lower-hanging near-term opportunities versus some of the initiatives that might be more long-term in nature, and how we should think about maybe how you're level-setting prioritization of those initiatives. Thanks.
Speaker #9: Perfect. All right. Fantastic. Thanks so much for the questions Hi. we go. here. James, welcome aboard.
Speaker #9: Get your feet—I know it's still early days, but it sounds like a better feel for the business. It would be—yep, we can hear you.
Speaker #9: Seeing some of the lower-hanging, you’ve been throwing a lot of facilities and getting more long-term in nature, and how we should think about near-term opportunities—maybe how your level. Thanks.
Speaker #9: Sure. First of all, thank you. It's great to be in here and, like you versus some of the initiatives that might be setting prioritization of those initiatives.
James Yamanaka: Sure. First of all, thank you. It's great to be in here. And like you said, it's been about a month since I've actually gotten into the role. And what I have been doing is visiting a lot of the facilities, meeting with the people. And the observation to me is it's a very strong company, good people, good capabilities, and a strong ability to grow into the future. In terms of the priorities, overall, look, I don't think it's a massive change after my first month. It'll always be focused on consumers, on the innovation, and on international expansion in the future to grow the business.
James Yamanaka: Sure. First of all, thank you. It's great to be in here. And like you said, it's been about a month since I've actually gotten into the role. And what I have been doing is visiting a lot of the facilities, meeting with the people. And the observation to me is it's a very strong company, good people, good capabilities, and a strong ability to grow into the future. In terms of the priorities, overall, look, I don't think it's a massive change after my first month. It'll always be focused on consumers, on the innovation, and on international expansion in the future to grow the business.
Speaker #9: I've actually gotten into the role, and what I have been doing is visiting a lot of the facilities, meeting with said—it's been about a month since the people—and the observation to me is it's a very strong company, good people, good capabilities.
Speaker #9: And a strong ability to grow into the future. In terms of the priorities, overall, look, I don't think it's a massive change after my first month.
Speaker #9: It'll always be focused on consumers, on the innovation, and on international expansion in the future to grow the business. In terms of the short-term priorities and the things that I think we need to focus on in the short term, it really is about operational execution, making sure that we really have a focus on executing with precision, focusing on the cost base, improving the margins, and make sure we deliver to the markets.
James Yamanaka: In terms of the short-term priorities and the things that I think we need to focus on in the short term, it really is about operational execution, making sure that we really have a focus on executing with precision, focusing on the cost base, improving the margins, and making sure we deliver to the markets. In the longer term, I think one of the reasons I was brought into the role was that over 20 years of international experience I've had. In fact, my entire career has been international markets. It's really looking at what are those future opportunities, balancing off sort of the risk, not overextending ourselves, but making sure we take advantage of the growth opportunities in the future. To sum it up, the fundamentals don't change.
James Yamanaka: In terms of the short-term priorities and the things that I think we need to focus on in the short term, it really is about operational execution, making sure that we really have a focus on executing with precision, focusing on the cost base, improving the margins, and making sure we deliver to the markets. In the longer term, I think one of the reasons I was brought into the role was that over 20 years of international experience I've had. In fact, my entire career has been international markets. It's really looking at what are those future opportunities, balancing off sort of the risk, not overextending ourselves, but making sure we take advantage of the growth opportunities in the future. To sum it up, the fundamentals don't change.
Speaker #9: term, I think one of the reasons I was brought into the role was In the longer that over 20 years of international experience I've had, in fact, my entire career has been international markets.
Speaker #9: And it's really opportunities, balancing off sort of the risk, not overextending ourselves, but making sure we take advantage of the growth opportunities in looking at what are those future, future.
Speaker #9: fundamentals don't change. But to sum it up, the The biggest focus is about execution and making sure we deliver on the numbers and improve our margins over time.
James Yamanaka: The biggest focus is about execution and making sure we deliver on the numbers and improve our margins over time, and also focusing on the cost base. Longer term, it's about well, mid to longer term, it's about expanding into those international markets prudently and making sure that we are able to grow the business sustainably.
James Yamanaka: The biggest focus is about execution and making sure we deliver on the numbers and improve our margins over time, and also focusing on the cost base. Longer term, it's about well, mid to longer term, it's about expanding into those international markets prudently and making sure that we are able to grow the business sustainably.
Speaker #9: Focusing on the cost base. Longer term, and also mid to longer term, it's about expanding into those international markets prudently and making sure that we are able to grow the business sustainably.
Speaker #8: Okay, great. Appreciate that, caller. Thank you. Second question from me, just
Aaron Grey: Okay. Great. Appreciate that, caller. Thank you. Second question for me, just in.
Aaron Grey: Okay. Great. Appreciate that, caller. Thank you. Second question for me, just in.
Speaker #8: in. All right.
Operator 3: Our next question comes from the line of Kenric Tyghe with Canaccord Genuity. Your line is open. Please go ahead.
Aaron Grey: Our next question comes from the line of Kenric Tyghe with Canaccord Genuity. Your line is open. Please go ahead.
Speaker #10: Next question comes from the line of Kendrick King with Canaccord Genuity. Your line is open. Please go ahead.
Speaker #11: Thank you. Good
Kenric Tyghe: Thank you. Good morning. James, congrats on the appointment. Just with respect to international volumes.
Kenric Tyghe: Thank you. Good morning. James, congrats on the appointment. Just with respect to international volumes.
Speaker #11: appointment. Just with respect to international ahead. volumes, thank you. With respect to international volumes, could you provide some insight on pastoral color around what happened on any indications of what was left on in second to that?
Aaron Grey: Thank you.
Aaron Grey: Thank you.
Kenric Tyghe: Thank you. With respect to international volumes, could you provide some insight on perhaps a little more color around what happened? And second to that, also on any indications of what was left on the table on the back of those flower issues? Essentially, what actions have you taken to address, and perhaps what did it cost in the quarter?
Kenric Tyghe: Thank you. With respect to international volumes, could you provide some insight on perhaps a little more color around what happened? And second to that, also on any indications of what was left on the table on the back of those flower issues? Essentially, what actions have you taken to address, and perhaps what did it cost in the quarter?
Speaker #11: the table on the back of those flower issues? Essentially, what actions have you taken to address and perhaps what did morning. quarter? And James, congrats on the
Speaker #9: Yeah. I think the first thing to note is Also,
James Yamanaka: Yeah. I think the first thing to note is that the requirements on international flower and the processes you can take in terms of processing the product are far more stringent in a lot of the international markets, and particularly in Germany, which is the fastest growing and largest of the international markets at the moment. What has happened is, as we mentioned, we had a fantastic increase in yields over the past year, which has meant we've had a lot more flower on hand, which has caused some issues in microbiome growth. We have identified what we believe are the core drivers. We're working on it to fix it. I do believe it's a temporary issue, and we should get back to supplying the market in the future. So that's what it is today. You asked as well about the exact effect.
James Yamanaka: Yeah. I think the first thing to note is that the requirements on international flower and the processes you can take in terms of processing the product are far more stringent in a lot of the international markets, and particularly in Germany, which is the fastest growing and largest of the international markets at the moment. What has happened is, as we mentioned, we had a fantastic increase in yields over the past year, which has meant we've had a lot more flower on hand, which has caused some issues in microbiome growth. We have identified what we believe are the core drivers. We're working on it to fix it. I do believe it's a temporary issue, and we should get back to supplying the market in the future. So that's what it is today. You asked as well about the exact effect.
Speaker #9: international flower and the processes you can take in terms of processing the product are far more stringent in a lot of the international markets, in particularly in Germany, which is the fastest growing and it cost in the largest of the international markets at the moment.
Speaker #9: happened is as we mentioned, we had a fantastic increase in yields over the past What has year, which has meant we've had a lot more flower on hand, which has caused microbiome growth.
Speaker #9: We have some issues in we believe are the core drivers. identified what on it to fix it. I do believe it's a temporary issue, and we should get back to supplying the market in the future.
Speaker #9: So that's what it is today. You asked as well about the exact effect. I might have to refer over to Greg for that, if there is an answer for that. Greg?
James Yamanaka: I might have to refer over to Greg for that, if there is an answer for that, Greg. Yeah?
James Yamanaka: I might have to refer over to Greg for that, if there is an answer for that, Greg. Yeah?
Speaker #9: Yeah?
Speaker #10: Yeah. Sure,
Greg Guyatt: Yeah. Sure, James. Hi, Kenric. We think that the impact of that was probably about CAD 3.5 million on revenue of international. So if you think about the fact that we hit CAD 5 million in Q1, which was a 50% improvement over last year, if we'd sort of had the normal on spec for flower, it would have been a pretty significant improvement relative to last year.
Greg Guyatt: Yeah. Sure, James. Hi, Kenric. We think that the impact of that was probably about CAD 3.5 million on revenue of international. So if you think about the fact that we hit CAD 5 million in Q1, which was a 50% improvement over last year, if we'd sort of had the normal on spec for flower, it would have been a pretty significant improvement relative to last year.
Speaker #10: James. Hi, Kendrick. We think that the impact of that was probably about three and a half million on revenue of international. So in Q1, which was a 50% we think about the fact that we hit 5 million improvement over last year.
Speaker #10: If we'd sort of had the normal on-spec for flower, it would have been a pretty significant year.
Kenric Tyghe: Thank you. Appreciate the granularity. I'll get back and queue.
Kenric Tyghe: Thank you. Appreciate the granularity. I'll get back and queue.
Speaker #11: Appreciate the granularity. I'll get back in Thank you.
Speaker #10: you.
James Yamanaka: Thank you.
James Yamanaka: Thank you.
Speaker #1: We have a question
Operator 4: We have a question again from Aaron Grey with Alliance Global Partners. Please go ahead. You're on stage.
James Yamanaka: We have a question again from Aaron Grey with Alliance Global Partners. Please go ahead. You're on stage.
Speaker #1: Again from Aaron Gray with Think Alliance Global Partners. Please go ahead, you're on.
Speaker #1: stage. Hi.
Speaker #8: Hi. Yeah. Good morning. improvement relative to last Yeah. I'll have a second one here. the international market now. So just to follow up on that real quick, and then I'll go to my second So I appreciate the call on question.
Aaron Grey: Hi. Yeah. Good morning. Yeah. I'll have a second one here. So, I appreciate the call on the international market now. So, just to follow up on that real quick, and then I'll go into my second question. Can you then utilize potentially that product? Can you reallocate it? I'll ask it that way. And then, kind of turning towards the Canadian market, do you feel a bit more confidence in terms of the snapback? It sounds like it was twofold. Number one, obviously, you guys had BC, so it sounds like that was more of a snapback. But then, second, we talked about more of the increased competitive nature of vapes and pre-rolls. Could you maybe talk about those two issues and how we should think about the recovery within the Canadian market? Thanks.
Aaron Grey: Hi. Yeah. Good morning. Yeah. I'll have a second one here. So, I appreciate the call on the international market now. So, just to follow up on that real quick, and then I'll go into my second question. Can you then utilize potentially that product? Can you reallocate it? I'll ask it that way. And then, kind of turning towards the Canadian market, do you feel a bit more confidence in terms of the snapback? It sounds like it was twofold. Number one, obviously, you guys had BC, so it sounds like that was more of a snapback. But then, second, we talked about more of the increased competitive nature of vapes and pre-rolls. Could you maybe talk about those two issues and how we should think about the recovery within the Canadian market? Thanks.
Speaker #8: Can you then utilize potentially that product? Can you reallocate it? I'll ask it that way. And then kind of turning towards the Canadian market, do you feel a bit more confident in terms of the snapback?
Speaker #8: It was twofold. Number one, obviously, you guys had BC, so it sounds like that was more of a snapback. But then, second, we talked about more, it sounds like, of the competitive nature—increased competitive nature—of vapes and pre-rolls.
Speaker #8: Could you maybe talk about those two issues and how we should think about the Canadian market? Thanks.
Speaker #9: Sure. I'll take those in different orders. So in terms
James Yamanaka: Sure. I'll take those in different orders. So in terms of BC, yes, I think we're back up. We are back up to the traditional distribution levels, so you would expect the sales to snap back in BC. In terms of the micro, I mean, the non-spec international, as I said, we've identified what we believe are the core drivers of that, which is very much about the good work the team has done on the yields, has created some issues. We are working on it. It's a top priority, and we expect that we will be resolving this issue. We don't think it's a permanent issue. And finally, as I mentioned in my statement in terms of the increased competitiveness, we do have new launches. We're fighting; we will fight back with new innovations and try to get there. But this is a very competitive part of the market.
James Yamanaka: Sure. I'll take those in different orders. So in terms of BC, yes, I think we're back up. We are back up to the traditional distribution levels, so you would expect the sales to snap back in BC. In terms of the micro, I mean, the non-spec international, as I said, we've identified what we believe are the core drivers of that, which is very much about the good work the team has done on the yields, has created some issues. We are working on it. It's a top priority, and we expect that we will be resolving this issue. We don't think it's a permanent issue. And finally, as I mentioned in my statement in terms of the increased competitiveness, we do have new launches. We're fighting; we will fight back with new innovations and try to get there. But this is a very competitive part of the market.
Speaker #9: are back up to the traditional distribution level. So you would expect the sales to snap back in BC. In terms of the about the recovery within micro I mean, the of BC, yes, I think we're back up.
Speaker #9: Non-spec international—as I said, we've identified what we believe are the core drivers of that. Which we see is very much about the good work the team has done on the yields, but that has created some issues.
Speaker #9: We and we expect that we will are working on it. It's a top priority, it's a permanent issue. And finally, as I mentioned in my statement in terms of the increased competitiveness, we do have new be resolving this issue.
Speaker #9: Fighting, we will fight back with new, very competitive parts of the market—innovations—and try to get there. But this is—so I would balance out the amount of investment we want to put in to say this would be one where we get that share back, balancing off the margins and making sure that we make the right decisions to get back to some growth.
James Yamanaka: So I would say this would be one where we balance out the amount of investment we want to put in to get that share back, balancing off the margins and making sure that we make the right decisions to get back to some growth there.
James Yamanaka: So I would say this would be one where we balance out the amount of investment we want to put in to get that share back, balancing off the margins and making sure that we make the right decisions to get back to some growth there.
Speaker #8: Hey, with a little bit of extra color on your question
Greg Guyatt: Hey, Erin. Greg here. May I just jump in with a little bit of extra color on your question about the international flower that was out of spec and can't be reallocated to other markets? Absolutely. So we have taken that flower and repurposed it towards the Canadian market. And there's no issues with it. It just didn't meet the needs for our international customer. So we're not expecting any inventory write-offs as a result of that.
Greg Guyatt: Hey, Erin. Greg here. May I just jump in with a little bit of extra color on your question about the international flower that was out of spec and can't be reallocated to other markets? Absolutely. So we have taken that flower and repurposed it towards the Canadian market. And there's no issues with it. It just didn't meet the needs for our international customer. So we're not expecting any inventory write-offs as a result of that.
Speaker #8: May I just jump in? No issues with it. It just didn't meet—we don't think—customer. So we're not expecting any inventory write-offs as a result of that.
Speaker #8: flower that was out of spec and
Speaker #8: canopy reallocated to other markets? Aaron. Absolutely. So we have taken Greg here. that flower and repurposed it towards the Canadian market. And there's there.
Speaker #8: Perfect. Thank you so much the needs for our international for the caller. I'll jump back in the queue.
Aaron Grey: Perfect. Thank you so much for the caller. I'll jump back in the queue.
Aaron Grey: Perfect. Thank you so much for the caller. I'll jump back in the queue.
Speaker #1: Our next call comes from ATB Capital Markets.
Speaker #1: Our next call comes from ATB Capital Markets. Your line is open. Go ahead, please.
Operator 4: Our next call comes from Brenda Cunningham from ATB Capital Markets. Your line is open. Please go ahead.
Aaron Grey: Our next call comes from Brenda Cunningham from ATB Capital Markets. Your line is open. Please go ahead.
Frederico Gomes: Hey. Good morning. Thanks for taking our questions. So just regarding the pending EU-GMP certification, it's good that you got some feedback. Some news is better than no news, right? We know that it's hard to predict. As we all know, regulators are unpredictable at best. But what type of timeline might we see for this coming through?
Frederico Gomes: Hey. Good morning. Thanks for taking our questions. So just regarding the pending EU-GMP certification, it's good that you got some feedback. Some news is better than no news, right? We know that it's hard to predict. As we all know, regulators are unpredictable at best. But what type of timeline might we see for this coming through?
Speaker #12: Good morning. And thanks for taking our questions.
Speaker #12: news, right? We know that it's hard to predict. As we all know, regulators are unpredictable at best. But what type of timeline might we see for this coming through?
Speaker #9: Yeah. I mean, where we are in the process right now, we've received some from Brianna Cunnington questions. We're working closely with them to resolve those issues.
James Yamanaka: Yeah. I mean, where we are in the process right now, we've received some feedback back from the regulators in January where they had some additional questions. We're working closely with them to resolve those issues and to answer those questions. In terms of timelines, we're working for the fastest we possibly can in conjunction with them. But like you said, these are regulators. So all we can do, we are doing our best to get it done as quickly as possible. But I can't give you a hard timeline at the moment. But we are working on the specific concerns they had and not concerns, but questions they had and clarifications they asked for. And we're working with them to try to get it as quickly as possible.
James Yamanaka: Yeah. I mean, where we are in the process right now, we've received some feedback back from the regulators in January where they had some additional questions. We're working closely with them to resolve those issues and to answer those questions. In terms of timelines, we're working for the fastest we possibly can in conjunction with them. But like you said, these are regulators. So all we can do, we are doing our best to get it done as quickly as possible. But I can't give you a hard timeline at the moment. But we are working on the specific concerns they had and not concerns, but questions they had and clarifications they asked for. And we're working with them to try to get it as quickly as possible.
Speaker #9: to answer those questions, And in terms of timelines, we're working for the fastest we possibly can in conjunction with them. But like you said, these are regulators.
Speaker #9: So all we can do, we are doing our best to get it done as quickly as possible. January, where they had some additional at the moment.
Speaker #9: But we But I can't are working on the specific give you a hard timeline concerns they had. clarifications they asked for. And we And not concerns, will we're working with them to try to get possible.
Speaker #12: Okay. Thank you so much. I'll jump back in the it as quickly as queue.
Frederico Gomes: Okay. Thank you so much. I'll jump back in the queue.
Frederico Gomes: Okay. Thank you so much. I'll jump back in the queue.
Operator 4: Our next question comes from the line of Pablo Zuanic from Zuanic & Associates. Your line is open. Please go ahead.
Frederico Gomes: Our next question comes from the line of Pablo Zuanic from Zuanic & Associates. Your line is open. Please go ahead.
Speaker #1: Our next question comes from Pablo Zlanek with Zlanek & Associates. Your line is open. Please go ahead.
Speaker #11: Thank you. And good morning, everyone. Can I ask you a question regarding route to market in Europe? I understand your work, obviously, with Sanity Group, in which you have an investment, BAT also has an investment in them.
Speaker #11: Thank you. And good morning, everyone. Can I ask you a question regarding route to market in Europe? I understand your work, obviously, with Sanity Group, in which you have an investment, BAT also has an investment in
Pablo Zuanic: Thank you. Good morning, everyone. Can I ask you a question regarding route to market in Europe? I understand you work, obviously, with Sanity Group, in which you have an investment. BAT also has an investment in them. You also work with other distributors. I'm just trying to understand, going forward, as you enter other markets, do you go direct? Do you go through Sanity? If you can just expand in terms of how you think about that? Thank you.
Pablo Zuanic: Thank you. Good morning, everyone. Can I ask you a question regarding route to market in Europe? I understand you work, obviously, with Sanity Group, in which you have an investment. BAT also has an investment in them. You also work with other distributors. I'm just trying to understand, going forward, as you enter other markets, do you go direct? Do you go through Sanity? If you can just expand in terms of how you think about that? Thank you.
Speaker #11: forward, as you enter other markets, do you go direct? Do you go through ahead. Sanity? If you can just expand in terms of how you you.
Speaker #9: Okay.
James Yamanaka: Okay. I'll start off with that, and maybe I'll hand over to Greg, who obviously has more time in the business than I do. I think the answer is that it will be a mix. Some of it, obviously, we sell to Sanity Group, which we do have an investment in. But as opportunities arise, there will be other models in different markets. So sometimes it'll be direct sales. Sometimes it'll be to Sanity. And it'll just depend on what the regulations require and what the best option, the most cost-effective way, and sustainable way, depending on the market it is. So I don't have a direct answer that would be consistent across all of them. Greg, do you have any comment on that?
James Yamanaka: Okay. I'll start off with that, and maybe I'll hand over to Greg, who obviously has more time in the business than I do. I think the answer is that it will be a mix. Some of it, obviously, we sell to Sanity Group, which we do have an investment in. But as opportunities arise, there will be other models in different markets. So sometimes it'll be direct sales. Sometimes it'll be to Sanity. And it'll just depend on what the regulations require and what the best option, the most cost-effective way, and sustainable way, depending on the market it is. So I don't have a direct answer that would be consistent across all of them. Greg, do you have any comment on that?
Speaker #9: I'll start off with that. And maybe I'll hand over to Greg, who obviously has more time in the business than I do. I think the answer is that it will be a mix.
Speaker #9: it, obviously, we sell to Sanity Group, as opportunities Some of which we do have an investment in. I'm just trying to understand, going arise, there will be other models in different But sales.
Speaker #9: Sometimes it'll be to markets. So sometimes it'll be direct what the regulations require and what the best option, the most Sanity. cost-effective way, and sustainable way And it'll just depend on depending on the market it is.
Speaker #9: a direct answer. That would be consistent across all of So I don't have
Speaker #9: that? Yeah.
Greg Guyatt: Yeah. I mean, thanks, Pablo. I mean, we ship direct to Germany, obviously, through our partner, Sanity. We also ship directly to the UK at the moment. I think as far as other markets in Europe, such as look at the likes of Czechia, Poland, and some of the others that are opening up, we have the ability to ship there directly. But we've got a great relationship with Sanity Group, so we're always in discussions about what the best way for us to go to market is. But at the moment, we ship direct to whichever markets we're competing in.
Greg Guyatt: Yeah. I mean, thanks, Pablo. I mean, we ship direct to Germany, obviously, through our partner, Sanity. We also ship directly to the UK at the moment. I think as far as other markets in Europe, such as look at the likes of Czechia, Poland, and some of the others that are opening up, we have the ability to ship there directly. But we've got a great relationship with Sanity Group, so we're always in discussions about what the best way for us to go to market is. But at the moment, we ship direct to whichever markets we're competing in.
Speaker #8: I mean, thanks, Pablo. I our partner, Sanity. We also
Speaker #8: At the moment, I think as far as other markets in Europe, such as, look at the likes of Czechia, obviously, through Poland, and some of the others that are opening up, we have the ability to—I mean, we ship direct to Germany, ship there directly.
Speaker #8: But we them.
Speaker #8: Sanity Group. So we're always in discussions about what the best also we've got a great relationship with way for us to go to market is.
Speaker #8: But at the moment, we ship direct to whichever markets we're competing.
Speaker #8: in. Great.
Speaker #11: Thank you. And then just a quick follow-up regarding the US. I know it's hard to Greg, do you have any comment on will evolve there.
Pablo Zuanic: Great. Thank you. And then just a quick follow-up regarding the US. I know it's hard to predict how the regulatory environment will evolve there, but you are one of the few Canadian LPs that's actually operating in the US market indirectly, right, through the two brands that you mentioned. In my opinion, the US market would consolidate very quickly. So how do you get ahead of that? I mean, can you make investments? Can you set up guardrails to do that and preserve your Nasdaq listing? Just trying to understand again, how do you think about accelerating M&A in the US market, and how do you protect your Nasdaq listing as you do that? Thank you.
Pablo Zuanic: Great. Thank you. And then just a quick follow-up regarding the US. I know it's hard to predict how the regulatory environment will evolve there, but you are one of the few Canadian LPs that's actually operating in the US market indirectly, right, through the two brands that you mentioned. In my opinion, the US market would consolidate very quickly. So how do you get ahead of that? I mean, can you make investments? Can you set up guardrails to do that and preserve your Nasdaq listing? Just trying to understand again, how do you think about accelerating M&A in the US market, and how do you protect your Nasdaq listing as you do that? Thank you.
Speaker #11: But you are one of predict how the regulatory environment operating in the Canadian in the US market market could consolidate very quickly. mentioned. In my opinion, the US up guardrails to do that and preserve mean, can you make investments?
Speaker #11: So how do you get ahead of that? I again, how do you think about indirectly, right, through two brands that you accelerating M&A in the US Can you set your NASDAQ listing as you do that?
Speaker #11: Thank
Speaker #11: you. Well, I think,
James Yamanaka: Well, I think, first of all, the Nasdaq listing does not allow us to do full investment in the US across all of the categories because of the state-by-state nature and the lack of federal regulation around it. So that would be a constraint on what we could invest in the US as a start. In terms of the current regulations, first of all, remember that the US is actually a relatively immaterial part of our business today. I think it's less than 1% of our revenues. And it's not crucial to the growth plans for Organigram. In terms of the regulatory situation, your guess is as good as ours. Under the current legislation, which is meant to go into effect in November, we're speaking with lawmakers, as are other parties. And we're hoping that we find a good resolution to this.
James Yamanaka: Well, I think, first of all, the Nasdaq listing does not allow us to do full investment in the US across all of the categories because of the state-by-state nature and the lack of federal regulation around it. So that would be a constraint on what we could invest in the US as a start. In terms of the current regulations, first of all, remember that the US is actually a relatively immaterial part of our business today. I think it's less than 1% of our revenues. And it's not crucial to the growth plans for Organigram. In terms of the regulatory situation, your guess is as good as ours. Under the current legislation, which is meant to go into effect in November, we're speaking with lawmakers, as are other parties. And we're hoping that we find a good resolution to this.
Speaker #9: first of all, the NASDAQ allow us to do full investment in the US across all
Speaker #9: federal regulation around it. So that would be a constraint on what we could invest in the listing does not
Speaker #9: US. As a start. In terms the state-by-state nature and the lack of
Speaker #9: Of the current regulations, first of all, remember that. Just trying to understand our business today. I think it's of the categories because it's less than 1% of our revenues.
Speaker #9: And it's not crucial to the growth plans relatively immaterial part of the regulatory situation, your guess market? is as good as ours.
Speaker #9: We, under the current legislation—which is meant to go into effect in November—are speaking with lawmakers, as we're hoping that we find a good resolution to this. There are other parties, and OGI is actually a part of that as well.
Speaker #9: We under the current And how do you protect legislation, which is meant to go into effect in are other parties, and US is actually a November, we're speaking with lawmakers, as we're hoping that we find a good for OrganicRAM.
James Yamanaka: But at the moment, we're creating different plans to make sure how we protect our current business in the US and set it up for you to make sure that we're there should federal regulation change at some point in the future. Again, Greg, do you have any other comment on that?
James Yamanaka: But at the moment, we're creating different plans to make sure how we protect our current business in the US and set it up for you to make sure that we're there should federal regulation change at some point in the future. Again, Greg, do you have any other comment on that?
Speaker #9: To make sure how we protect our current business in the U.S., and set it up to make sure that we're there should federal regulation change at some point in the future.
Speaker #9: Again, Greg, do you have any other comment on the moment, we're creating different plans that? In terms of
Greg Guyatt: Yeah. Thanks, James. No, I think you hit most of the key points there. The one additional thing I would add is, given the regulatory uncertainty, we're not investing really heavily in the US right now. We're kind of waiting to see what happens. We're continuing to support the existing business, investing in sales and marketing, and so forth. But really, until we start to see some clarity around regulation, I think we're going to be prudent as to how much capital we deploy in that market, particularly given the size of that business for us today. Obviously, we hope that things get clarified in the coming months. But right now, I think we just need to kind of wait and see what happens. And we'll continue to focus on other international markets where we see the bigger growth opportunities for us in the short term.
Greg Guyatt: Yeah. Thanks, James. No, I think you hit most of the key points there. The one additional thing I would add is, given the regulatory uncertainty, we're not investing really heavily in the US right now. We're kind of waiting to see what happens. We're continuing to support the existing business, investing in sales and marketing, and so forth. But really, until we start to see some clarity around regulation, I think we're going to be prudent as to how much capital we deploy in that market, particularly given the size of that business for us today. Obviously, we hope that things get clarified in the coming months. But right now, I think we just need to kind of wait and see what happens. And we'll continue to focus on other international markets where we see the bigger growth opportunities for us in the short term.
Speaker #8: Of the key points there, the one additional thing: regulatory uncertainty. We're not investing really heavily in the US right now. We're kind of waiting to see what happens.
Speaker #8: of the key points there. The one additional thing regulatory uncertainty, we're not investing really heavily in the US right now. We're kind of Yeah.
Speaker #8: the existing business, investing in sales and marketing and so forth. But really, until we start to think we're going to be prudent see some clarity around regulation, I market, particularly given the size of Obviously, we hope that things get Thanks, James. that business for us today.
Speaker #8: The existing business, investing in sales and marketing, and so forth. But really, until we start to think—we're going to be prudent, see some clarity around regulation and market, particularly given the size of that business for us today. Obviously, we hope that things get clarified in the coming months. Thanks, James.
Speaker #8: the existing business, investing in sales and marketing and so forth. But really, until we start to think we're going to be prudent see some clarity around regulation, I market, particularly given the size of Obviously, we hope that things get Thanks, James.
Speaker #8: happens. And we'll continue to focus on other international markets But right now, I think we just need to kind of wait and see what
Speaker #8: term. as to how much capital we deploy in that
Speaker #11: Got it. Thank you. That's good calling. Thank
Pablo Zuanic: Got it. Thank you. That's a good call-up. Thank you.
Pablo Zuanic: Got it. Thank you. That's a good call-up. Thank you.
Speaker #1: Just a reminder, if you would like to question, press star one call comes from Kendrick Tighe. From Canaccord Genuity,
Operator 4: Just a reminder, if you would like to ask any questions, please press star 1. And to withdraw your question, press star 1 again. Our next call comes from Kenric Tyghe from Canaccord Genuity. Your line is open. Please go ahead.
Pablo Zuanic: Just a reminder, if you would like to ask any questions, please press star 1. And to withdraw your question, press star 1 again. Our next call comes from Kenric Tyghe from Canaccord Genuity. Your line is open. Please go ahead.
Speaker #1: ask any questions, please
Speaker #1: ask any questions, please
Speaker #1: your line is open. Please go
Speaker #8: Thank you. And apologies for the follow-up. Just with respect to the increased competition that you where we see the bigger growth opportunities for called out in pre-rolls, did that also translate into increased And why is that increased competition across all markets and pretty us in the short And I think you hit most broad-based?
Aaron Grey: Thank you. And apologies for the follow-up. Just with respect to the increased competition that you called out in pre-rolls, did that also translate into increased promotional intensity in quarter? And was that increased competition across all markets and pretty broad-based, or was it pretty narrow and only in specific markets?
Aaron Grey: Thank you. And apologies for the follow-up. Just with respect to the increased competition that you called out in pre-rolls, did that also translate into increased promotional intensity in quarter? And was that increased competition across all markets and pretty broad-based, or was it pretty narrow and only in specific markets?
Speaker #8: Or was it pretty narrow
Speaker #8: markets? promotional intensity in quarter?
James Yamanaka: On this one, Greg, can you provide some color? Again, I apologize. It's been a month in. Greg, do you have any color on that one?
James Yamanaka: On this one, Greg, can you provide some color? Again, I apologize. It's been a month in. Greg, do you have any color on that one?
Speaker #9: one, Greg, can you provide some color? Again, I apologize. It's been a month
Speaker #9: that one?
Speaker #8: Yeah. No problem, James. Yeah. On this you. Kendrick, I'd say it's a competitive space in general. All the categories have pretty again. intense competition.
Speaker #8: Yeah. No problem, James. Yeah. On this you. Kendrick, I'd say it's a competitive space in general. All the categories have pretty
Greg Guyatt: Yeah. No problem, James. Yeah. Kendrick, I'd say it's a competitive space in general. All the categories have pretty intense competition. I think when it comes to pre-rolls and IPRs, we're seeing the value proposition really evolving across the entire industry. Similar to what we've seen in prior quarters, the potencies are increasing. Pricing's become more competitive. We're confident that we have great offerings coming and in the pipeline that are going to address those challenges. But that's sort of what we're seeing across the category, pricing coming down and potency being the key challenge. The rest of the industry, I mean, we're seeing sort of similar levels of competition across vapes versus what we had in the prior quarter. Flower is always competitive. We think we've got a really great foothold there. And then in the beverage space, with the shots coming out, we're very optimistic about that.
Greg Guyatt: Yeah. No problem, James. Yeah. Kendrick, I'd say it's a competitive space in general. All the categories have pretty intense competition. I think when it comes to pre-rolls and IPRs, we're seeing the value proposition really evolving across the entire industry. Similar to what we've seen in prior quarters, the potencies are increasing. Pricing's become more competitive. We're confident that we have great offerings coming and in the pipeline that are going to address those challenges. But that's sort of what we're seeing across the category, pricing coming down and potency being the key challenge. The rest of the industry, I mean, we're seeing sort of similar levels of competition across vapes versus what we had in the prior quarter. Flower is always competitive. We think we've got a really great foothold there. And then in the beverage space, with the shots coming out, we're very optimistic about that.
Speaker #8: to pre-rolls and Our next ahead. IPRs, we're seeing the value proposition to what we've seen in really evolving across the entire prior quarters, the potencies are increasing.
Speaker #8: become more Pricing's have great offerings coming and in the pipeline that are going to address those competitive. We're confident that we challenges. But that's sort of what we're seeing across the industry.
Speaker #8: being the key challenge. The rest of the industry, I mean, we're of similar levels of competition across vapes versus what we had in the prior always competitive.
Speaker #8: We think we've got a really great Similar foothold there. And then in quarter. the beverage space, Flower is with the shots coming out, we're very optimistic about that.
Greg Guyatt: The current product portfolio, we think there's some good growth opportunities there. Really looking forward to the new offerings coming and higher potencies across pre-rolls, which I think will position us really well to compete effectively in all of those categories.
Greg Guyatt: The current product portfolio, we think there's some good growth opportunities there. Really looking forward to the new offerings coming and higher potencies across pre-rolls, which I think will position us really well to compete effectively in all of those categories.
Speaker #8: we think there's some good growth opportunities seeing sort there. So really, looking forward to the new offerings coming. And higher potencies And the current product portfolio, in across pre-rolls, which I think will position us really well to compete effectively in all of those Greg.
Speaker #8: Thanks very much,
Aaron Grey: Thanks so much, Greg. I'll leave it there.
Aaron Grey: Thanks so much, Greg. I'll leave it there.
Speaker #8: I'll leave it there.
Speaker #1: There are no categories. further questions at this time. I
Operator 4: There are no further questions at this time. I will now turn the call back to James Yamanaka, CEO, for closing remarks.
Aaron Grey: There are no further questions at this time. I will now turn the call back to James Yamanaka, CEO, for closing remarks.
Speaker #1: Yamanaka, CEO for Closing
Speaker #1: Remarks. First of all, thank you
James Yamanaka: First of all, thank you for joining the call today. Thank you for the questions. I'm looking forward to more of these going forward and as I get my feet on the table a bit more to be able to give you a little more clarity on some of the future of the business. Thank you very much for your attendance today. I'll pass it back over to the moderator.
James Yamanaka: First of all, thank you for joining the call today. Thank you for the questions. I'm looking forward to more of these going forward and as I get my feet on the table a bit more to be able to give you a little more clarity on some of the future of the business. Thank you very much for your attendance today. I'll pass it back over to the moderator.
Speaker #8: for joining the call today. And thank you for the questions I'm looking forward to more of these going the table a bit more, to be clarity on some of the future of the forward. able to give you a little more today.
Speaker #8: for joining the call today. And thank you for the questions I'm looking forward to more of these going the table a bit more, to be clarity on some of the future of the forward.
Speaker #8: business. So thank you very much for your attendance And as I get my feet on
Speaker #8: And I'll pass it back over to the
Speaker #8: moderator. Thank you.
Operator 4: Thank you. This concludes today's call. Thank you for attending. You may now disconnect.
James Yamanaka: Thank you. This concludes today's call. Thank you for attending. You may now disconnect.
Speaker #1: This concludes attending. You may now today's call. Thank you for
